Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance

摘要

Erythropoeitin dose variation in different facilities in different countries and its relationship to drug resistance.BackgroundThe correction of anemia using erythropoeitin (EPO) is accorded high priority in the management of patients undergoing hemodialysis (HD). Target hemoglobin (Hb) levels have been established in many countries. Following an observation that the mean facility EPO dose in a chain of facilities in the United States varied by more than two-fold, an examination of the practice of anemia correction in other settings was carried out.